Distinguished Faculty Lecture Series: Jonathan Xavier Inda, "Racial Prescriptions: Pharmaceuticals, Difference, & the Politics of Life" Response by Rico Kleinstein Chenyek
Wednesday, February 25, 2015
posted under
by Unknown
[On February 23, the Unit for Criticism & Interpretive Theory hosted the latest installment in its 2014-2015 Distinguished Faculty Lecture Series, “Racial Prescriptions: Pharmaceuticals, Difference, & the Politics of Life.” The speaker was Jonathan Xavier Inda, Chair & Associate Professor of Latina/Latino Studies. Professor Monica McDermott (Sociology) responded. Below are reflections on the event from graduate student Rico Kleinstein Chenyek.]
Molecular Vital Politics of Race: Affirming Life Through Biopower and BiDil
Written by Rico Kleinstein Chenyek (Phd/MD Student: Institute for Communications Research, Medical Scholars Program, & Latina/Latino Studies)
In the age of genomics and individualized genetic health sciences, scholars have begun to explore the implications of new forms of medicalized racialization. Jonathan Inda’s (Latina/Latino Studies/ Anthropology) Unit for Criticism and Interpretive Theory Distinguished Faculty Lecture, "Racial Prescriptions: Pharmaceuticals, Difference, & the Politics of Life,” addressed the double-edged effects of recent scientific research to develop pharmaceuticals targeted at racial minorities, such as the drug BiDil, which was marketed to African Americans. Following an introduction by Alejandro Lugo (Anthropology/Latina/Latino Studies) who located Inda’s current research on race and medicine work within the context of his earlier and ongoing research on immigration, criminalization, governmentality, and the regulation of citizenship (see Targeting Immigrants, among others), Inda introduced the main object of his study: isosorbide dinitrate/hydralazine HCL, or BiDil®.
Prof. Inda’s talk and its title were drawn from his recent monograph, which explores the politics of dealing with health disparities by developing and marketing pharmaceuticals targeted at specific racial minorities. BiDil is a pharmaceutical drug developed by Dr. Jay Cohn to treat congestive heart failure by opening blood vessels so the heart does not work as hard, thereby relieving some of the symptoms. In the late 1990s, after initial clinical trials designed for the general population produced inconclusive results, the Food & Drug Administration (FDA) rejected the drug. However, Dr. Cohn later developed a study for BiDil with only self-identified African Americans. This study showed a significant increase in survival and quality of life for those who took BiDil in comparison with the controlled placebo group. In fact, as the homepage for BiDil.com for health professionals advertises in one of their “Did You Know” facts, “the African American Heart Failure Trial (A-HeFT) was terminated early following a recommendation from the independent Data Safety Monitoring Board due to a significantly lower mortality rate in the BiDil group.” In other words, since the study showed quick and pronounced benefits, the trial was cut short. With these new results, Dr. Cohn returned to the FDA seeking approval for the drug. He also buttressed his case by drawing the support of numerous Black professional, political, and medical organizations, who were motivated by the urgent need to address racial health disparities in their community. Cohn received approval of the drug for use only for self-identified African Americans, making it, in June 2005, the first and only pharmaceutical approved by FDA for a specific racial group to this day.
Inda argues that the BiDil case study is crucial to understanding new forms of the biologization of race in the wake of the mapping of the human genome in 2000 and the renewed impetus given to genetic solutions to racial health disparities. Inda points out that we must approach the case of BiDil with caution because while this research is driven by the effort to improve the health of racial minorities, such efforts may reinforce the biologization of race and allow for the economic exploitation of racial minorities. Building on Michel Foucault’s concept of “biopower” via Paul Rabinow and Nikolas Rose, Inda examines BiDil as imbricated in the new racial politics of life, where the racial body becomes an object of vitality. Foucault’s biopower shows how a series of measures aimed at improving health and increasing wealth can also contain a murderous and exclusionary underside. Rose and Rabinow situate biopower as a logic of vitality in the context of genetic and biological sciences that envision life to be molecularly artificial thereby rendering vitality readily engineerable. Placing this work in conversation with Duana Fullwiley’s observations about the contemporary “molecular inscription of race,” Inda considers the racial politics of BiDil’s development and marketing. As a project of biological citizenship and a biochemical materialization of hope, BiDil was touted by its backers as something that recognized African American lives as worthy of health care while aiming to reduce cardiovascular health disparities within the group. BiDil was supported by Black and other minoritized professionals and by Black political, health, and medical organizations.
However, Inda contends that BiDil is far from problem-free on both scientific and political fronts. Scientifically, through its approval as a drug only for African Americans, BiDil gives the impression that it will work for all African Americans and only for African Americans, thus flattening out the heterogeneity of Blackness, genetically and otherwise. Furthermore, in standing out as the only drug approved solely for African Americans, it ignores the overwhelming consistency in drug response across racial difference as demonstrated by Steven Epstein. Ultimately, in approving BiDil solely for those that self-identify as African Americans, a process of racialization and self-identification that is extremely varied gets reduced to a specific biological difference whose genetic basis remains uncertain to this day. (There is no genetic or otherwise biological marker that determines BiDil sensitivity in people with congestive heart failure based on self-identification.)
Politically, the argument for BiDil is extremely tenuous as well. On one hand, following the work of Jonathan Kahn, as scientists and health providers and researchers increasingly understand health disparities through the lens of genetics, the social, physical, and environmental origins of racial health disparities lose the attention and resources required for structural change. On the other hand, following the work of Sharona Hoffman, Inda argues that BiDil could contribute to the same racial stigmatization and discrimination Black people experienced in finding employment and insurance coverage following the imagined genetic associations made between sickle-cell anemia and blackness.
Following Dr. Inda’s talk, Monica McDermott (Sociology) provided a response commenting on the importance of critiquing how science and medicine assert power within our current political reality, especially as they appears to foster life rather than explicitly seeking to eradicate it. Thus, McDermott contends that in a postracial era that figures race as a legacy of the past that is no longer tied to ongoing discrimination, not only does medical racialization do violence to non-white subjects, but it also justifies the withdrawal of necessary social welfare and support. While McDermott understands how Black people and organizations welcomed the targeted research and recognition of African American health inequalities in the development of BiDil, she reiterates Inda’s critiques. She observes that BiDil is capable of producing a crisis of identity in, for example, a hypothetical self-identified African American seeking an effective treatment through BiDil based solely on racial identification, but who does not respond favorably to the drug. McDermott further argues that such biological renderings of race reify racial admixture as somehow less real. They also contribute to the same line of thinking that produces the white supremacist desire to locate particular combinations of genes, such as a “warrior gene,” that would identify and explain the source of violence and aggression in Black and Latino inner-city youth.
Following the formal lecture, attendees engaged in thought-provoking discussion linking Inda’s research to developments in epigenetics that explores how the environment may become coded in one’s DNA and how such a line of thinking may similarly bolster arguments about cultural deficiency or poor childrearing as the cause behind racial health disparities. Questions also yielded discussions regarding the possible future discovery of a biological factor linked to BiDil sensitivity that would then potentially show race to be irrelevant to BiDil efficacy. Another thread in the discussion focused on the overall failure of BiDil to bring awareness about congestive heart failure or to reach the global market as developers had initially hoped. Inda pointed out that strategies of moving pharmaceutical drugs to racially-specific markets overseas have emerged such as in the case of Iressa, a drug used in lung cancer treatment, which was developed in the US and later marketed in Asia as racially specific for Asians. The discussion concluded with Inda’s reflection on the connection between his earlier work and this research as being shaped by a concern with examining processes of racialization.
Molecular Vital Politics of Race: Affirming Life Through Biopower and BiDil Written by Rico Kleinstein Chenyek (Phd/MD Student: Institute for Communications Research, Medical Scholars Program, & Latina/Latino Studies)
In the age of genomics and individualized genetic health sciences, scholars have begun to explore the implications of new forms of medicalized racialization. Jonathan Inda’s (Latina/Latino Studies/ Anthropology) Unit for Criticism and Interpretive Theory Distinguished Faculty Lecture, "Racial Prescriptions: Pharmaceuticals, Difference, & the Politics of Life,” addressed the double-edged effects of recent scientific research to develop pharmaceuticals targeted at racial minorities, such as the drug BiDil, which was marketed to African Americans. Following an introduction by Alejandro Lugo (Anthropology/Latina/Latino Studies) who located Inda’s current research on race and medicine work within the context of his earlier and ongoing research on immigration, criminalization, governmentality, and the regulation of citizenship (see Targeting Immigrants, among others), Inda introduced the main object of his study: isosorbide dinitrate/hydralazine HCL, or BiDil®.
Prof. Inda’s talk and its title were drawn from his recent monograph, which explores the politics of dealing with health disparities by developing and marketing pharmaceuticals targeted at specific racial minorities. BiDil is a pharmaceutical drug developed by Dr. Jay Cohn to treat congestive heart failure by opening blood vessels so the heart does not work as hard, thereby relieving some of the symptoms. In the late 1990s, after initial clinical trials designed for the general population produced inconclusive results, the Food & Drug Administration (FDA) rejected the drug. However, Dr. Cohn later developed a study for BiDil with only self-identified African Americans. This study showed a significant increase in survival and quality of life for those who took BiDil in comparison with the controlled placebo group. In fact, as the homepage for BiDil.com for health professionals advertises in one of their “Did You Know” facts, “the African American Heart Failure Trial (A-HeFT) was terminated early following a recommendation from the independent Data Safety Monitoring Board due to a significantly lower mortality rate in the BiDil group.” In other words, since the study showed quick and pronounced benefits, the trial was cut short. With these new results, Dr. Cohn returned to the FDA seeking approval for the drug. He also buttressed his case by drawing the support of numerous Black professional, political, and medical organizations, who were motivated by the urgent need to address racial health disparities in their community. Cohn received approval of the drug for use only for self-identified African Americans, making it, in June 2005, the first and only pharmaceutical approved by FDA for a specific racial group to this day.
 |
| Image taken from Bidil.com homepage |
However, Inda contends that BiDil is far from problem-free on both scientific and political fronts. Scientifically, through its approval as a drug only for African Americans, BiDil gives the impression that it will work for all African Americans and only for African Americans, thus flattening out the heterogeneity of Blackness, genetically and otherwise. Furthermore, in standing out as the only drug approved solely for African Americans, it ignores the overwhelming consistency in drug response across racial difference as demonstrated by Steven Epstein. Ultimately, in approving BiDil solely for those that self-identify as African Americans, a process of racialization and self-identification that is extremely varied gets reduced to a specific biological difference whose genetic basis remains uncertain to this day. (There is no genetic or otherwise biological marker that determines BiDil sensitivity in people with congestive heart failure based on self-identification.)
 |
| Jonathan Xavier Inda (Photo Credit: Rico Chenyek) |
Following Dr. Inda’s talk, Monica McDermott (Sociology) provided a response commenting on the importance of critiquing how science and medicine assert power within our current political reality, especially as they appears to foster life rather than explicitly seeking to eradicate it. Thus, McDermott contends that in a postracial era that figures race as a legacy of the past that is no longer tied to ongoing discrimination, not only does medical racialization do violence to non-white subjects, but it also justifies the withdrawal of necessary social welfare and support. While McDermott understands how Black people and organizations welcomed the targeted research and recognition of African American health inequalities in the development of BiDil, she reiterates Inda’s critiques. She observes that BiDil is capable of producing a crisis of identity in, for example, a hypothetical self-identified African American seeking an effective treatment through BiDil based solely on racial identification, but who does not respond favorably to the drug. McDermott further argues that such biological renderings of race reify racial admixture as somehow less real. They also contribute to the same line of thinking that produces the white supremacist desire to locate particular combinations of genes, such as a “warrior gene,” that would identify and explain the source of violence and aggression in Black and Latino inner-city youth.
Following the formal lecture, attendees engaged in thought-provoking discussion linking Inda’s research to developments in epigenetics that explores how the environment may become coded in one’s DNA and how such a line of thinking may similarly bolster arguments about cultural deficiency or poor childrearing as the cause behind racial health disparities. Questions also yielded discussions regarding the possible future discovery of a biological factor linked to BiDil sensitivity that would then potentially show race to be irrelevant to BiDil efficacy. Another thread in the discussion focused on the overall failure of BiDil to bring awareness about congestive heart failure or to reach the global market as developers had initially hoped. Inda pointed out that strategies of moving pharmaceutical drugs to racially-specific markets overseas have emerged such as in the case of Iressa, a drug used in lung cancer treatment, which was developed in the US and later marketed in Asia as racially specific for Asians. The discussion concluded with Inda’s reflection on the connection between his earlier work and this research as being shaped by a concern with examining processes of racialization.
0 comments:
Post a Comment